Literature DB >> 28737048

Ototoxicity monitoring in children treated with platinum chemotherapy.

Beth Brooks1, Kristin Knight2.   

Abstract

OBJECTIVE: To review the prevalence, mechanisms, clinical presentation, risk factors and implications of platinum-induced ototoxicity in paediatric cancer patients based on published evidence, discuss options for monitoring hearing in young children during treatment and review long-term follow-up guidelines.
DESIGN: Narrative literature review.
RESULTS: Children treated with cisplatin are at high risk of hearing loss and early, accurate identification of ototoxicity is important for medical decision making and hearing rehabilitation. Challenges of monitoring hearing in young children during cancer treatment and options for monitoring hearing are discussed.
CONCLUSION: Hearing loss has important consequences for the survivors of childhood cancer including communication, learning, cognition and quality of life. Due to the presentation and configuration of ototoxic hearing loss, the test frequencies that are prioritised and the sequence of testing may differ from standard paediatric hearing evaluations. Hearing should be monitored during treatment and after completion of therapy.

Entities:  

Keywords:  Hearing loss; carboplatin; children; cisplatin; ototoxicity

Mesh:

Substances:

Year:  2017        PMID: 28737048     DOI: 10.1080/14992027.2017.1355570

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  16 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

Review 2.  Monitoring Protocols for Cochlear Toxicity.

Authors:  Sherman G Lord
Journal:  Semin Hear       Date:  2019-04-26

3.  Clinical trials, ototoxicity grading scales and the audiologist's role in therapeutic decision making.

Authors:  Kelly A King; Carmen C Brewer
Journal:  Int J Audiol       Date:  2017-12-23       Impact factor: 2.117

Review 4.  Common Aminoglycosides and Platinum-Based Ototoxic Drugs: Cochlear/Vestibular Side Effects and Incidence.

Authors:  Robert M DiSogra
Journal:  Semin Hear       Date:  2019-04-26

5.  Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.

Authors:  Anna Rita Fetoni; Francesca Brigato; Eugenio De Corso; Daniela Lucidi; Bruno Sergi; Emanuele Scarano; Jacopo Galli; Antonio Ruggiero
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-13       Impact factor: 3.236

Review 6.  Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity.

Authors:  Sofia Waissbluth; Juan Cristóbal Maass; Helmuth A Sanchez; Agustín D Martínez
Journal:  Front Neurosci       Date:  2022-04-27       Impact factor: 4.677

7.  Cisplatin is retained in the cochlea indefinitely following chemotherapy.

Authors:  Andrew M Breglio; Aaron E Rusheen; Eric D Shide; Katharine A Fernandez; Katie K Spielbauer; Katherine M McLachlin; Matthew D Hall; Lauren Amable; Lisa L Cunningham
Journal:  Nat Commun       Date:  2017-11-21       Impact factor: 14.919

8.  Vestibulotoxicity Associated With Platinum-Based Chemotherapy in Survivors of Cancer: A Scoping Review.

Authors:  Pattarawadee Prayuenyong; John A Taylor; Stephanie E Pearson; Rachel Gomez; Poulam M Patel; Deborah A Hall; Anand V Kasbekar; David M Baguley
Journal:  Front Oncol       Date:  2018-09-25       Impact factor: 6.244

9.  A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.

Authors:  E Clemens; B Brooks; A C H de Vries; M van Grotel; M M van den Heuvel-Eibrink; B Carleton
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

Review 10.  Prevention of Noise-Induced Hearing Loss Using Investigational Medicines for the Inner Ear: Previous Trial Outcomes Should Inform Future Trial Design.

Authors:  Colleen G Le Prell
Journal:  Antioxid Redox Signal       Date:  2021-10-04       Impact factor: 7.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.